Prodalim in the first quarter: the new engine is working, but cash is still funding the proof

Prodalim opened 2026 with a quarter that confirms the shift into higher-value activity, but still does not close the cash test. Specialty Ingredients is already moving the group: revenue jumped to $19.7 million, adjusted EBITDA rose to $3.6 million, and the segment’s share of group profitability grew much faster than its share of revenue. At group level, however, revenue rose only 4.4%, adjusted EBITDA barely changed, and net profit fell to $1.5 million because of IPO expenses, share-based payments and expansion costs. Operating cash flow turned positive, mainly because inventory was released, but the all-in cash picture before new equity was still negative by about $34 million after Sylvestre, CAPEX, repayments, interest and leases. The IPO gives the company real time, with $84.3 million of cash and lower net financial debt, so this is not an immediate liquidity issue. The proof point now moves to the next quarters: organic growth in Specialty Ingredients, conversion of Solos into visible revenue, and working capital that does not reabsorb the improvement.

What The Company Really Sells Now

Prodalim operates in natural solutions for the food, beverage, flavor and fragrance industries. The legacy engine is Juice Solutions, still most of the revenue. The quality engine is Specialty Ingredients, where the company sells extracts, flavors, natural colors, fibers and compounds to the beverage and food industries. Solos is the more distant growth layer: technology and services for reducing and removing alcohol while preserving aroma and taste.

The numbers make the hierarchy clear. In the first quarter, Juice Solutions generated $71.5 million of revenue and $8.3 million of adjusted EBITDA. Specialty Ingredients generated $19.7 million of revenue and $3.6 million of adjusted EBITDA. Solos is still tiny, with $394 thousand of revenue and an adjusted EBITDA loss of $305 thousand.

The market still treats the company as a business that needs proof. At the beginning of May, the market cap was about NIS 2.14 billion, close to the pre-money valuation in the IPO, about NIS 2.1 billion. That fits the question raised in the previous annual analysis: whether the move into higher-value activities will also reach cash, or mostly stay in segment profitability and growth presentations.

Specialty Ingredients Pulls Up, But The Group Is Not Fully There

The quarter has real edge because total growth hides a strong internal shift. Group revenue rose from $87.7 million to $91.5 million, but Specialty Ingredients alone grew 64%, from $12.0 million to $19.7 million. Adjusted EBITDA in the segment almost doubled from $1.8 million to $3.6 million, and the adjusted EBITDA margin rose from 15.3% to 18.2%.

Not all of this improvement is mechanical. The company attributes the growth mainly to René Laurent, acquired in December 2025, but also reports about 27% organic growth. That is the difference between accounting consolidation of an acquired activity and a sign that the commercial base is working. Still, a large part of the 2026 read has to use a pro forma base, because acquisitions have changed the comparison point.

The chart shows why the group picture is less clean than the Specialty Ingredients story. Juice Solutions revenue fell 5% and adjusted EBITDA fell 15%, which the company attributes to timing of customer drawdowns under framework agreements. In the quarter itself, that decline erased a large part of the Specialty Ingredients jump. The next question is therefore not only whether SIS keeps growing, but whether Juice Solutions stabilizes enough for the improvement to reach the group line.

Profit also needs separation. Net profit fell from $3.4 million to $1.5 million, but adjusted net profit rose from $3.3 million to $3.9 million after excluding one-time items, mainly IPO expenses and share-based payments. The adjustment is reasonable for understanding the quarter, but it does not settle the cost-base question for a newly public company that is expanding through acquisitions, labs and service centers.

Cash Flow Improved, But The IPO Still Funds The Transition

The largest improvement in the quarter is operating cash flow. After negative operating cash flow of $22.9 million in the comparable quarter and negative $5.4 million for all of 2025, the first quarter ended with positive operating cash flow of $15.0 million. The main driver was a $26.3 million inventory release, after a year in which working capital was one of the central bottlenecks.

But that is not the full cash picture. Before new equity, after operating cash flow, acquisitions, reported CAPEX, capitalized development costs, debt repayments, interest and lease principal repayment, the company still used about $34.2 million. This is the all-in cash-use picture for a transition period, not an estimate of normalized cash generation from the existing business.

The IPO changed the balance sheet in one move: cash rose to $84.3 million, equity to $238.7 million, and net financial debt fell to $45.8 million from $107.7 million at the end of March 2025. So the issue is not immediate liquidity. The issue is the quality of cash use: whether the new equity funds acquisitions that return cash, or buys time until the new activities mature.

Sylvestre is a good test case. The company paid about $31 million and will pay another roughly $2 million over six years. Sylvestre generated about $9.7 million of 2025 revenue, about $3.3 million of EBITDA and an EBITDA margin of roughly 34%, so strategically it fits Specialty Ingredients. But the purchase price allocation is still provisional: out of a $33.1 million purchase cost, identified net assets are only $3.7 million and goodwill is $29.5 million. A large part of the value depends on synergy, cross-selling and margin retention, not on assets already measured.

Solos raises a different proof bar. Revenue rose from $294 thousand to $394 thousand, but operating loss widened to $433 thousand. At the same time, the company is expanding its growth infrastructure: a Solos site in Valencia, a California facility, application labs in Spain, the U.S. and Slovenia, and Better Juice sugar-reduction technology with expected production in Florida in the second half of 2026. These are operating milestones, not commercial proof. For the market to read Solos as an engine rather than a cost center, revenue needs to start moving faster than setup costs.

Conclusion

The current read on Prodalim is more positive on the business side and more cautious on cash. Specialty Ingredients moved in the first quarter from a promise engine to a segment that actually changes segment profitability, and organic growth prevents the argument that everything is only acquisition consolidation. On the other side, reported profit fell, Solos remains small and loss-making, and Sylvestre is still mostly goodwill and expected synergy.

The strongest counter-thesis is that the quarter already delivered what a company at this stage should deliver: a jump in Specialty Ingredients, positive operating cash flow, lower net debt and a large post-IPO cash balance. That is reasonable, but it becomes a full conclusion only if it repeats. In the coming quarters the market will look for three signs: SIS continuing to grow above the acquisition base without EBITDA erosion, working capital staying controlled, and Solos beginning to show utilization and revenue that justify the service-center network. The first quarter improves the direction. It still does not close the proof.